news-med.jpg

Evotec and Immuneering to collaborate on Artificial Intelligence (“AI”) driven ligand identification for rare hereditary metabolic diseases

Combination of cutting-edge IPSC and AI technologies creates opportunity to discover novel metabolic ligands to accelerate drug discovery in rare metabolic diseases

Topics: Corporate, Evotec, Immuneering, metabolic diseases, artificial intelligence, IPSC Read More

Evotec and Celgene expand IPSC collaboration to include additional cell lines

$ 6 M payment to access additional cell lines

Topics: Corporate, Evotec, Celgene, IPSC, Induced pluripotent stem cells Read More

Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Topics: Corporate, Evotec, Drug Discovery, CENTOGENE, rare genetic diseases, IPSC Read More

Evotec and Celgene expand IPSC collaboration to include additional cell lines

$ 6 M payment to access additional cell lines

Topics: Corporate, Celgene, IPSC, Evotec Read More

Most Read

Posts by Topic